Aplicacion de la medicina nuclear en el Instituto de Hematología: resultados más relevantes

Fundora Sarraff, Teresa A; Fernández Delgado, Norma; Gautier du Défaix Gómez, Hortensia; Macías Abraham, Consuelo; Valle Pérez, Lázaro del; Martínez Antuña, Gisela; Hernández Ramírez, Porfirio; Ballester Santovenia, José M.
Rev. cuba. hematol. inmunol. hemoter ; 20(2)mayo-ago. 2004. tab
Artigo em Espanhol | LILACS | ID: lil-400277

Documentos relacionados

  1. EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials.
  2. Current status and future perspective of radiopharmaceuticals in China.
  3. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides.
  4. Highlights of the 25th Anniversary EANM Congress Milan 2012: nuclear medicine and molecular imaging at its best.
  5. Reconciling Mouse and Human Immunology at the Altar of Genetics.
  6. Synthesis of <sup>177</sup>Lu-Labeled, Somatostatin-2 Receptor-Targeted Metalla-Assemblies: Challenges in the Design of Supramolecular Radiotherapeutics.
  7. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.
  8. European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees.
  9. Letter to Editor for "European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees."
  10. Development of novel radionuclides for medical applications.